Allerfex® (Tablets) Instructions for Use
Marketing Authorization Holder
Severnaya Zvezda NAO (Russia)
ATC Code
R06AX26 (Fexofenadine)
Active Substance
Fexofenadine (Rec.INN registered by WHO)
Dosage Forms
| Allerfex® | Film-coated tablets, 30 mg: 10, 20, or 30 pcs. | |
| Film-coated tablets, 120 mg: 10, 20, or 30 pcs. | ||
| Film-coated tablets, 180 mg: 10, 20, or 30 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets from pink to dark pink in color, round, biconvex; the core of the tablets on the cross-section is white or almost white.
| 1 tab. | |
| Fexofenadine hydrochloride | 30 mg |
Excipients: microcrystalline cellulose 102 – 21.5 mg, calcium hydrogen phosphate dihydrate – 5 mg, potato starch – 7.5 mg, croscarmellose sodium (primellose) – 4 mg, magnesium stearate – 0.75 mg, talc – 0.75 mg, colloidal silicon dioxide (aerosil) – 1.5 mg, povidone K30 (medium molecular weight polyvinylpyrrolidone) – 4 mg.
Shell composition hypromellose – 1 mg, polysorbate-80 (tween-80) – 0.4 mg, talc – 0.4 mg, titanium dioxide (E171) – 0.184 mg, aluminum lake based on dye azorubine (E122) – 0.016 mg).
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer bottles (1) – cardboard packs.
Film-coated tablets from pink to dark pink in color, round, biconvex; the core of the tablets on the cross-section is white or almost white.
| 1 tab. | |
| Fexofenadine hydrochloride | 120 mg |
Excipients: microcrystalline cellulose 102 – 86 mg, calcium hydrogen phosphate dihydrate – 20 mg, potato starch – 30 mg, croscarmellose sodium (primellose) – 16 mg, magnesium stearate – 3 mg, talc – 3 mg, colloidal silicon dioxide (aerosil) – 6 mg, povidone K30 (medium molecular weight polyvinylpyrrolidone) – 16 mg.
Shell composition hypromellose – 4.5 mg, polysorbate-80 (tween-80) – 1.8 mg, talc – 1.8 mg, titanium dioxide (E171) – 0.828 mg, aluminum lake based on dye azorubine (E122) – 0.072 mg).
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer bottles (1) – cardboard packs.
Film-coated tablets from pink to dark pink in color, round, biconvex; the core of the tablets on the cross-section is white or almost white.
| 1 tab. | |
| Fexofenadine hydrochloride | 180 mg |
Excipients: microcrystalline cellulose 102 – 129 mg, calcium hydrogen phosphate dihydrate – 30 mg, potato starch – 45 mg, croscarmellose sodium (primellose) – 24 mg, magnesium stearate – 4.5 mg, talc – 4.5 mg, colloidal silicon dioxide (aerosil) – 9 mg, povidone K30 (medium molecular weight polyvinylpyrrolidone) – 24 mg.
Shell composition hypromellose – 7 mg, polysorbate-80 (tween-80) – 2.8 mg, talc – 2.8 mg, titanium dioxide (E171) – 1.288 mg, aluminum lake based on dye azorubine (E122) – 0.112 mg).
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer bottles (1) – cardboard packs.
Clinical-Pharmacological Group
Histamine H1-receptor blocker. Antiallergic drug
Pharmacotherapeutic Group
Antiallergic agent – H1-histamine receptor blocker
Pharmacological Action
Histamine H1-receptor blocker. Fexofenadine is a pharmacologically active metabolite of terfenadine. Does not have a sedative effect.
The antihistamine effect appears within 1 hour, reaches a maximum after 6 hours, and lasts for 24 hours. After 28 days of administration, no tolerance was observed.
It has been established that when taken orally in the dose range from 10 mg to 130 mg, the efficacy of fexofenadine is dose-dependent.
Pharmacokinetics
After oral administration, it is rapidly absorbed from the gastrointestinal tract, Cmax is determined after 1-3 hours. The mean Cmax after a 180 mg dose is approximately 494 ng/ml, and after a 120 mg dose – 427 ng/ml. Plasma protein binding is 60-70%. T1/2 after multiple doses is 11-15 hours. It is excreted in breast milk. 5% of the dose undergoes partial extrahepatic metabolism. It is excreted mainly with bile (80%), 10% is excreted by the kidneys unchanged.
Indications
Relief of symptoms associated with seasonal allergic rhinitis, symptomatic treatment of chronic urticaria.
ICD codes
| ICD-10 code | Indication |
| J30.1 | Allergic rhinitis due to pollen |
| L50 | Urticaria |
| ICD-11 code | Indication |
| CA08.00 | Allergic rhinitis due to pollen |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For adults and children over 12 years of age, the recommended daily dose is 120 mg to 180 mg taken once daily.
Select the appropriate tablet strength to achieve the prescribed total daily dose.
Administer the tablet orally with a glass of water.
Take the dose before a meal to ensure consistent absorption.
For patients with renal impairment, use with caution; a reduced dosage of 60 mg once daily may be necessary.
For patients with hepatic impairment, use with caution and consider a reduced dosage.
Do not exceed the maximum recommended daily dose of 180 mg.
For pediatric patients aged 6 to 11 years, the recommended dose is 30 mg twice daily.
The use of this drug in children under 6 years of age is not recommended.
In elderly patients, use with caution and at the lowest effective dose.
If a dose is missed, take it as soon as remembered; if it is near the time for the next dose, skip the missed dose.
Do not take a double dose to make up for a forgotten one.
Maintain an interval of at least 2 hours between taking this drug and aluminum- or magnesium-containing antacids.
Adverse Reactions
Possible headache, drowsiness, dizziness, fatigue, nausea, lethargy, increased fatigue.
Contraindications
Pregnancy, lactation period, children under 6 years of age, hypersensitivity to fexofenadine.
Use in Pregnancy and Lactation
Fexofenadine is contraindicated for use during pregnancy and during the lactation period (breastfeeding).
Fexofenadine passes into breast milk. If it is necessary to use fexofenadine during lactation, the issue of discontinuing breastfeeding should be decided.
Use in Hepatic Impairment
Use with caution in patients with hepatic insufficiency.
Use in Renal Impairment
Use with caution in patients with renal insufficiency.
Pediatric Use
The use of the drug in children under 6 years of age is not recommended.
Geriatric Use
Use with caution in elderly patients.
Special Precautions
Use with caution in elderly patients, in patients with renal or hepatic insufficiency.
The efficacy and safety of fexofenadine in children under 6 years of age have not been studied.
Effect on the ability to drive vehicles and mechanisms
Based on the pharmacodynamic profile and known side effects, it can be assumed that the effect of fexofenadine on the ability to drive a car and engage in activities requiring increased concentration is unlikely. Objective studies have shown that Fexofenadine does not have a significant effect on CNS functions. Nevertheless, it is recommended to check the individual reaction before driving a car or engaging in other potentially hazardous activities.
Drug Interactions
Fexofenadine is not biotransformed in the liver and therefore does not interact with other drugs undergoing hepatic metabolism.
It has been shown that with the simultaneous use of fexofenadine with erythromycin or ketoconazole, the plasma concentration of fexofenadine increases by 2-3 times, which is apparently associated with an increase in absorption from the gastrointestinal tract and with a reduction in either bile excretion or gastrointestinal secretion. At the same time, no changes in the QT interval were observed.
When taking aluminum- or magnesium-containing antacids 15 minutes before taking fexofenadine, a decrease in its bioavailability was observed, most likely due to binding in the gastrointestinal tract. The recommended time interval between taking fexofenadine and antacids containing aluminum or magnesium hydroxide is 2 hours.
Does not interact with omeprazole, with drugs metabolized in the liver.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Picamilon pills 50mg, 60pcs
Ingavirin capsules 90mg, 10pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Fenotropil pills 100mg, 60pcs
Belosalic, lotion solution for external use spray 100ml
Arbidol, capsules 100mg, 40pcs
Phenibut-Vertex pills 250mg, 20pcs
Mildronate capsules 500mg, 90pcs
Actovegin pills 200mg, 50pcs
Nootropil pills 800mg, 30pcs
Kagocel pills 12mg, 30pcs
Daivobet, ointment, 30g
Cavinton Comfort, dispersible pills 10mg 90pcs
OKI, sachets 80mg 2g, 12pcs
Cortexin, 10mg, 5ml, 10pcs 